Mr. Squarer has served as a member of the Board of Directors of Deciphera Pharmaceuticals since December 2019 and as Chairperson of the Board since June 2023. He has over 30 years of experience in the pharmaceutical and biotechnology industry. Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. (Array) from 2012 until its acquisition by Pfizer Inc. in August 2019 following the successful commercial launches of both Braftovi® and Mektovi®. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development, when Mayne was sold to Hospira in 2007. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer Inc. (focused on oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. He currently serves on the Board of Directors of Travere Therapeutics, Inc., formerly Retrophin, Inc. and of ADC Therapeutics SA. Mr. Squarer received a bachelor’s degree in biochemistry from the University of California, Berkeley and an M.B.A. from the Kellogg School of Management, Northwestern University.
